359 related articles for article (PubMed ID: 23031671)
21. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.
Schwesinger C; Yee C; Rohan RM; Joussen AM; Fernandez A; Meyer TN; Poulaki V; Ma JJ; Redmond TM; Liu S; Adamis AP; D'Amato RJ
Am J Pathol; 2001 Mar; 158(3):1161-72. PubMed ID: 11238064
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy for the treatment of ocular neovascularization.
Bradley J; Ju M; Robinson GS
Angiogenesis; 2007; 10(2):141-8. PubMed ID: 17372853
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
24. Metabolic physiology in age related macular degeneration.
Stefánsson E; Geirsdóttir A; Sigurdsson H
Prog Retin Eye Res; 2011 Jan; 30(1):72-80. PubMed ID: 20951826
[TBL] [Abstract][Full Text] [Related]
25. The VEGF paradox: Does diabetic retinopathy protect from age related macular degeneration?
Saravia M; Zeman L; Ingolotti M; Schlaen A
Med Hypotheses; 2017 Nov; 109():156-161. PubMed ID: 29150277
[TBL] [Abstract][Full Text] [Related]
26. Does laser still have a role in the management of retinal vascular and neovascular diseases?
Shah AM; Bressler NM; Jampol LM
Am J Ophthalmol; 2011 Sep; 152(3):332-339.e1. PubMed ID: 21742309
[TBL] [Abstract][Full Text] [Related]
27. Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.
Stalmans I
Verh K Acad Geneeskd Belg; 2005; 67(4):229-76. PubMed ID: 16334858
[TBL] [Abstract][Full Text] [Related]
28. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.
Zhang SX; Wang JJ; Gao G; Parke K; Ma JX
J Mol Endocrinol; 2006 Aug; 37(1):1-12. PubMed ID: 16901919
[TBL] [Abstract][Full Text] [Related]
29. Rat strain-dependent susceptibility to ischemia-induced retinopathy associated with retinal vascular endothelial growth factor regulation.
Lu K; Zhou Y; Kaufman K; Mott R; Ma JX
J Mol Endocrinol; 2007 Apr; 38(4):423-32. PubMed ID: 17446232
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.
Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Caldwell RW
Diabetes Metab Res Rev; 2003; 19(6):442-55. PubMed ID: 14648803
[TBL] [Abstract][Full Text] [Related]
31. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
[TBL] [Abstract][Full Text] [Related]
32. Monitoring ocular drug therapy by analysis of aqueous samples.
Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
[TBL] [Abstract][Full Text] [Related]
33. Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options.
Wallsh JO; Gallemore RP
Cells; 2021 Apr; 10(5):. PubMed ID: 33946803
[TBL] [Abstract][Full Text] [Related]
34. Müller cell-derived VEGF is a significant contributor to retinal neovascularization.
Bai Y; Ma JX; Guo J; Wang J; Zhu M; Chen Y; Le YZ
J Pathol; 2009 Dec; 219(4):446-54. PubMed ID: 19768732
[TBL] [Abstract][Full Text] [Related]
35. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment.
Takahashi K; Saishin Y; Saishin Y; Silva RL; Oshima Y; Oshima S; Melia M; Paszkiet B; Zerby D; Kadan MJ; Liau G; Kaleko M; Connelly S; Luo T; Campochiaro PA
FASEB J; 2003 May; 17(8):896-8. PubMed ID: 12670875
[TBL] [Abstract][Full Text] [Related]
36. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
37. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.
Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852
[TBL] [Abstract][Full Text] [Related]
38. [Alternative splicing of vascular endothelial growth factor A and ocular neovascularization].
Fan SJ; He SZ
Zhonghua Yan Ke Za Zhi; 2011 Apr; 47(4):373-7. PubMed ID: 21612688
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
[TBL] [Abstract][Full Text] [Related]
40. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion.
Noma H; Funatsu H; Mimura T; Eguchi S; Hori S
Am J Ophthalmol; 2011 Oct; 152(4):669-677.e1. PubMed ID: 21726846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
